Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Vinorelbine

Cisplatin

Tubulin Modulators

Antimitotic Agents

Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)

Cisplatin IV

Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36

Radiotherapy

Chrystèle LOCHER, MD

The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.

Concomitant Radio-chemotherapy in the Elderly

Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC

Pierre Fabre Laboratories

University Hospital, Limoges

Infections

Wounds and Injuries

Symptoms and General Pathology

Pneumonia

Radiation Pneumonitis

Communicable Diseases

Respiratory Tract Infections

Lung Diseases, Interstitial

Lung Injury

Radiation Injuries

Patients with locally advanced lung cancer who are candidates to chemoradiation

Oscar Arrieta, MD

Lung cancer \[LC\] is the leading cause of cancer death worldwide. The standard treatment of locally advanced lung cancer unresectable or marginally resectable is combination therapy with radical or preoperative chemoradiation. The local control rates and survival with this treatment modality have increased by more than 30%. Radiotherapy \[RT\] with technical molded 3D \[3D-CRT, Three-Dimensional Conformal Radiation Therapy\] or IMRT \[intensity-modulated radiation therapy\] has allowed that the total dose of radiation has increased which leads to a direct benefit on the results treatment.

Between 17-30% of patients are susceptible to pneumonitis due to radiation \[NR\]. This complication may appear at the end of the RT or up to 6 months after the treatment. In severe cases, mortality can reach 50%.

It's well known that in various diseases, functional abnormalities precede the clinical manifestations. The degree of pulmonary failure secondary to RT is measured following the standards of the Radiation Therapy Oncology Group who ranks in degrees \[0 to 4\].

Not precisely known factors that influence the development of NR.

Objectives:

To evaluate the effect of chemotherapy and thoracic radiotherapy on pulmonary function and identify predictors of radiation pneumonitis in locally advanced lung cancer \[stages IIIA and IIIB\].

Hypothesis:

Respiratory function tests may predict the development of radiation pneumonitis in patients with locally advanced lung cancer who receive radical treatment with chemoradiation.

Methods Prospective cohort study with patients with locally advanced lung cancer of the Lung Cancer Clinic of the National Cancer Institute \[INCAN\]. Patients will receive weekly paclitaxel 50 mg and carboplatin AUC 2 with concomitant radiotherapy 44-63 Gy (22-33 fractions). Followup of lung function tests at baseline, during treatment with radiotherapy and will be carried out on 4 more occasions.

Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation

Clinical, Biochemical, Dosimetric and Functional Respiratory Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer (Stages IIIa and IIIb) Treated With Chemotherapy and Radiotherapy

National Council of Science and Technology, Mexico

Instituto Nacional de Cancerologia de Mexico

Chief of Thoracic Oncology Department

Pemetrexed

Vorinostat

Histone Deacetylase Inhibitors

Enzyme Inhibitors

Dose escalation of vorinostat, cisplatin, pemetrexed and radiation

vorinostat once daily for 12 weeks of therapy

vorinostat

Ranee Mehra, MD

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine MTD of the combination.

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

National Comprehensive Cancer Network

Fox Chase Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Concomitant Radio-chemotherapy in the Elderly	NCT01029678	Non Small Cell ...	Cisplatin IV Vinorelbine Radiotherapy	70 Years -	University Hospital, Limoges
Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation	NCT01580579	Radiation; Adve...		18 Years -	Instituto Nacional de Cancerologia de Mexico
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT01059552	Locally Advance...	vorinostat	18 Years -	Fox Chase Cancer Center

Spots Global Cancer Trial Database for locally advanced lung cancer